(0.11%) 5 254.35 points
(0.12%) 39 807 points
(-0.12%) 16 379 points
(-0.07%) $83.11
(-0.62%) $1.752
(0.73%) $2 254.80
(0.74%) $25.10
(1.45%) $922.85
(0.04%) $0.927
(0.19%) $10.86
(-0.04%) $0.792
(-0.03%) $92.55
-1.40% ¥ 2 650.00
Live Chart Being Loaded With Signals
Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan. The company offers three-part and five-part white blood cell differentiation instruments for use in hematology; and transport systems for high-volume testing in labs...
Stats | |
---|---|
Today's Volume | 227 600 |
Average Volume | 1.68M |
Market Cap | 1 700.04B |
EPS | ¥0 ( 2024-02-08 ) |
Next earnings date | ( ¥66.07 ) 2024-05-08 |
Last Dividend | ¥2.00 ( 2023-03-30 ) |
Next Dividend | ¥0 ( N/A ) |
P/E | 36.84 |
ATR14 | ¥1.918 (0.07%) |
Volume Correlation
Sysmex Corporation Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Sysmex Corporation Correlation - Currency/Commodity
Sysmex Corporation Financials
Annual | 2022 |
Revenue: | ¥410.50B |
Gross Profit: | ¥216.08B (52.64 %) |
EPS: | ¥218.83 |
Q3 | 2023 |
Revenue: | ¥113.83B |
Gross Profit: | ¥60.76B (53.38 %) |
EPS: | ¥58.86 |
Q2 | 2023 |
Revenue: | ¥117.35B |
Gross Profit: | ¥60.61B (51.65 %) |
EPS: | ¥64.81 |
Q1 | 2023 |
Revenue: | ¥95.35B |
Gross Profit: | ¥50.41B (52.87 %) |
EPS: | ¥41.20 |
Financial Reports:
No articles found.
Sysmex Corporation Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
¥40.00 (N/A) |
¥0 (N/A) |
¥2.00 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | ¥1.500 | 2001-03-27 |
Last Dividend | ¥2.00 | 2023-03-30 |
Next Dividend | ¥0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 46 | -- |
Total Paid Out | ¥628.25 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 4.35 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 6.49 | |
Div. Directional Score | 9.63 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
9039.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
8163.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
7570.T | Ex Dividend Junior | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
6810.T | Ex Dividend Knight | 2023-09-28 | Annually | 0 | 0.00% | |
6210.T | Ex Dividend Junior | 2023-09-28 | Annually | 0 | 0.00% | |
4967.T | Ex Dividend Knight | 2023-12-28 | Semi-Annually | 0 | 0.00% | |
4189.T | Ex Dividend Knight | 2023-12-28 | Semi-Annually | 0 | 0.00% | |
3402.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
2491.T | Ex Dividend Knight | 2023-12-28 | Semi-Annually | 0 | 0.00% | |
9663.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.103 | 1.500 | 7.94 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0794 | 1.200 | 7.35 | 8.82 | [0 - 0.3] |
returnOnEquityTTM | 0.112 | 1.500 | 9.87 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.390 | -1.000 | 6.10 | -6.10 | [0 - 1] |
currentRatioTTM | 3.10 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 1.972 | 0.800 | 3.11 | 2.49 | [0.8 - 2.5] |
cashRatioTTM | 0.603 | 1.500 | 7.76 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.0882 | -1.500 | 8.53 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 37.92 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 325.14 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 85.74 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.123 | -1.500 | 9.51 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.532 | 1.000 | 4.47 | 4.47 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.168 | 1.000 | 8.65 | 8.65 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 1.355 | 1.000 | 3.58 | 3.58 | [0.2 - 2] |
assetTurnoverTTM | 0.773 | 0.800 | 8.18 | 6.55 | [0.5 - 2] |
Total Score | 12.77 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 12.49 | 1.000 | 8.84 | 0 | [1 - 100] |
returnOnEquityTTM | 0.112 | 2.50 | 9.92 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 85.74 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 3.19 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 325.14 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.390 | 1.500 | 6.10 | -6.10 | [0 - 1] |
pegRatioTTM | 0.328 | 1.500 | -1.146 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.155 | 1.000 | 8.63 | 0 | [0.1 - 0.5] |
Total Score | 6.49 |
Sysmex Corporation
Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan. The company offers three-part and five-part white blood cell differentiation instruments for use in hematology; and transport systems for high-volume testing in labs. It also provides urine formed sediment analysis systems; automated immunochemistry systems, which perform assays on minute sample quantities, as well as reagents to test for infectious disease and tumor markers; and flow cytometers to perform analysis in diagnosing leukemia, malignant lymphoma, and HIV/AIDS. In addition, the company offers cancer lymph node metastasis testing systems to detect information to help in diagnosing lymph node metastasis; cancer genome profiling systems; and cytogenic testing and lab assay services. It is also involved in the development and sale of software for diagnostic information systems; provision of facility management, office, and welfare services; development, manufacture, and sale of nucleic acid analogs; development, operation, and maintenance of IT solutions, platforms, and applications related to digital medicine; marketing, development, design, manufacture, sale, and after-sales service related to medical robots; and distribution and after sales support of medical devices and reagents for biotechnology, medical technology, and molecular cell analysis. The company serves national and other public hospitals, private hospitals, universities, research institutes, other medical institutions, etc. It also exports its products to approximately 190 countries. Sysmex Corporation has a strategic alliance with QIAGEN N.V. for the development and commercialization of cancer companion diagnostics using Plasma-Safe-SeqS technology. The company was formerly known as TOA Medical Electronics Co., Ltd. and changed its name to Sysmex Corporation in October 1998. Sysmex Corporation was founded in 1968 and is headquartered in Kobe, Japan.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators